 hold pt downgrad hold valuat believ posit price
beyondspr inc buy pt first nda file horizon china think take capit get
finish line lower pt analyst jason mccarthi ph full summari
 buy pt continu strength oliv garden still expect gradual rebound
optim dose analyst jason mccarthi ph full summari
 buy pt tripl combo glioblastoma first patient
inc buy pt overreact concern propos chang offic view
trovagen inc trov buy pt second program initi enrol zytiga prostat
enterpris consum technolog cryptocurr deep dive read-through stx tsm cryptocurr suppli
corpor event call maxim salesperson inform
annual summer confer host vendetti chokshi jang abwn bhtg
cover hq visit orlando ceo gene cfo cardena
annual summer confer host vendetti chokshi jang abwn bhtg
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
annual silicon valley bu tour host chokshi tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
alarm com hold inc cover chokshi ndr milwauke cfo steve valenzuela tue sep
profir energi inc pfie cover jang ndr boston ceo brenton hatch cfo ryan oviatt tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
downgrad hold valuat believ posit
price share maintain pt
downgrad share hold buy
share price reach price target yesterday
cake comp growth acceler see renew margin expans
buyback potenti acquisit contribut least low-teen ep
growth believ posit price share
ep estim unchang vs consensu
vs consensu vs consensu
share risen year-to-d vs industri averag
drop year-to-d trade forward price-to-earnings in-line five-year
downgrad share price reach price target yesterday
amid broader ralli casual dine share follow
buy strong earn report highlight benefit follow
factor believ continu next quarter
comp growth high end guidanc sever
top-lin lever dispos includ off-premis sale saturday brunch
estim ad cumul comp
specif regard june estim above-consensu comp
vs street easier y/i weather comparison strong quarter-to-d
return modest margin expans despit high labor cost light
benign food cost guidanc provid yesterday believ relief protein
cost result food cost inflat rang current guidanc
moreov estim return averag sg spend
total sale would add much annual ep
strong free cash flow post-dividend free cash flow run
pace cash use
buyback estim add ep
much would surpris see announc
dividend boost and/or acceler buy-back program yesterday
potenti acquisit believ like acquir north italia
minor stake parallel cake exist strength includ
broad demograph reach focus real estat strategi class-a mall
provid readi new unit growth catalyst appear pois view
gain market share although potenti support ep growth
cake current low-teen ep growth guidanc caution time
acquisit remain uncertain inde manag decid upon make
acquisit see note june detail
nevertheless believ strong year-to-d perform
share fairli valu cake forward price-to-earnings multipl vs five-year
averag forward ev/ebitda multipl vs five-year averag
light strong year-to-d ralli share price includ ralli
past week alon believ potenti upsid growth
balanc potenti risk notabl higher labor cost uncertain
click full note
overreact concern propos chang
offic view reiter buy target
stock declin yesterday attribut concern
privat offic usp part broader propos
chang govern propos presid trump
think unlik chang usp would neg impact
would use pullback buy opportun
potenti chang made usp would improv financi
condit maintain competit posit versu carrier would
posit view
remain posit earn outlook gener base
high margin modest capital-expenditure leverag e-commerce high volum
reiter buy rate price target base
non-gaap ep estim
view pullback stock attract buy opportun yesterday
stock declin propos restructur usp includ
presid trump deliv govern solut centuri reform
reorgan recommend report present recogn
challeng usp face high fix cost univers servic oblig
along declin tradit mail unfund liabil report propos
privat usp review expans price packag deliveri
market uspss role competit market provid univers servic
among area think congress would need approv ultim
chang also believ contribut usp one area
growth packag would expect continu support think
action improv financi strength usp continu invest
packag market would posit also note usp
keep price packag competit privat carrier
recommend report expect avail august
remain posit attract earn outlook model five-
year organ revenu ep growth compound-annual-growth-rate least growth outlook
support stmp leverag attract e-commerce trend gain market share
robust solut marketplac new offer intern
small/hom offic enterpris solut busi provid cheaper
solut compar postal meter
strong free cash flow conserv balanc sheet invest
posit view high margin modest capit expenditur support healthi
gener compani lever relat acquisit activ
quickli paid debt expect priorit toward organ
growth buyback debt pay down model compani end
net cash per share
reiter buy rate price target would use yesterday
pullback buy opportun given view support
usp area growth key futur stock current trade
ep estim price target base
non-gaap ep estim
click full note
cryptocurr deep dive read-
through stx tsm
capital-expenditure reduc peak level consist econom theori
believ cryptocurr valuat remain state bubbl
bring addit risk memori fabless semi suppli chain player
key compon enabl cryptocurr mine
normal valuat pt alreadi account
risk nand flash oversuppli
capital-expenditure reduc peak level consist econom theori
figur plot usd/bitcoin price bitcoin hash rate increment
bitcoin hash rate focu increment hash rate metric directli
correl increment hardwar purchas bitcoin mine recogn
cryptocurr move unison bitcoin increment bitcoin
hash rate serv proxi overal cryptocurr mine hardwar demand
analysi data indic cryptocurr capital-expenditure like peak januari
one month usd/bitcoin price peak monthli capital-expenditure trend
monthli peak level util taiwan tsm nr
disclosur cryptocurr relat demand repres revenu
triangul term arm-bas comput demand comput
architectur util cryptocurr mine cryptocurr relat demand peak
arm comput declin see figur
page also develop econom model understand
usd/bitcoin price drive increment capital-expenditure time break-even contour chart
present figur page one may expect declin usd/cryptocurr
result declin overal hash rate thu risk cryptocurr mine hardwar
dump second hand market
believ cryptocurr valuat remain state bubbleon page
address believ conveni cryptocurr improv
time still inferior current domin payment rail thu limit abil
one mani cryptocurr becom de facto global currenc also
address store valu argument find primari util cryptocurr
data immut properti deriv use underli blockchain
innov histor small nich market
call inform archiv market vs current aggreg market cap
cryptocurr recogn may properti
act potenti non-depreci store valu increas
data immut present understand lead us conclud cryptocurr
declin fraction current valuat despit alreadi declin
cryptocurr valuat decemb peak believ best
current cryptocurr price stabil continu declin valu
scenario lead depress hardwar relat demand level see section
rel peak level
bring addit risk memori fabless semi suppli chain player
key compon enabl cryptocurr mine page address
expect declin demand cryptocurr relat hardwar impact
memori market remain bias downcycl immin note
price target alreadi take scenario account
also address potenti valu stx stake rippl privat
largest cryptocurr market cap
click full note
first nda file horizon china think
take capit get finish line lower pt
maintain buy rate though lower price
target follow releas march result
report net loss end period
cash combin capit rais may estim compani
cash balanc sheet runway late
adjust oper expens higher late stage pivot program advanc
expect compani need rais capit factor
model combin reduc price target
current valuat compani leav plenti upsid
next key inflect file nda plinabulin china late
pend posit outcom interim analysi program studi
chemotherapy-induc neutropenia cin
interim data plinabulin docetaxel cin
file nda china cin late
data plinabulin tac induc cin late
interim data plinabulin docetaxel lung cancer
file nda china lung cancer
initi pipelin combin program immune-oncolog
conclus first nda file come year neulasta space gain
investor attent first biosimilar approv nr
 buy far behind novemb plinabulin
differenti potenti larger market opportun pivot data next
plinabulin vs neulasta biosimilar neulasta first biosimilar neulasta
approv earli june fulphilia coheru
expect approv novemb view plinabulin differenti
approach treating/prev neutropenia signific opportun take share
pegfilgrastim space even biosimilar lower price enter
market well opportun expand market moder risk neutropenia
neulasta challeng time given chemo patient inconveni
given earli bone marrow hit chemo bone pain
overstimul bone marrow overshoot neutrophil count
immun suppress neutrophil/lymphocyt ratio high surviv neulasta
demonstr improv surviv
plinabulin overcom neulasta challeng time given time
chemotherapi patient go home bone pain plin preserv neutrophil
chemo stimul bone marrow small molecul growth factor
click full note
tripl combo glioblastoma
inovio announc first patient dose trial immunotherapi
glioblastoma gbm tripl combin
go tripl doubl ad well
inovio multipl dna base immun therapi candid oncolog
infecti diseas demonstr signific induct tumor
target cell basi incorpor checkpoint
addit dna-bas given abil amplifi immun respons
well drive activ layer immun respons could
synergist vaccin checkpoint gbm studi enrol
patient across site
also evalu bladder cancer partner medimmun
azn nr develop hpv-associ
potenti catalyst continu see data updat
multipl trial begin report later year addit
program continu move forward provid catalyst stock
program enrol data expect
view potenti transform event compani
combin checkpoint checkpoint inhibitor releas break
cell block receptor prevent identifi cancer cell
foreign allow patient immun system fight cancer mechan
led adopt integr part cancer treatment paradigm inovio
cancer vaccin natur synergi checkpoint gener
addit cell target specif antigen present cancer cell
combin increas immun respons site tumor allow
checkpoint inhibitor lead improv surviv major player space
identifi opportun inovio on-going partnership
medimmun azn nr roche/genentech nr regeneron nr
hpv-relat diseas target multipl indic addit
pivot program cervic dysplasia describ inovio conduct
open-label studi high-grad hpv-relat precancer lesion
vulva trial evalu regress lesion viral clearanc
vulvar tissu third in-hous program initi may target
anal perian high grade squamou intraepitheli lesion hsil open-label
studi enrol subject receiv least three dose partner
medimmun licens inovio refer
initi new clinic trial evalu durvalumab pd-
metastat hpv-associ head neck cancer scchn
pivot cervic dysplasia first two studi on-going
second expect initi data expect
click full note
continu strength oliv garden still expect
gradual rebound cheddar maintain buy pt
maintain buy rate price target
follow releas better-than-expect may result above-
believ dri underli fundament trend remain solid think
could upsid blend comp growth guidanc posit
thank continu comp strength dri legaci concept return
comp growth cheddar
also see upsid potenti project margin growth
solid free cash flow support healthi dividend sustain buyback
turn gener sharehold return mid-to-high teen
accord model
ep estim unchang august
may ep estim guidanc
well pre-releas consensu
rais ep fiscal year estim vs
pre-releas consensu
comp estim guidanc posit unchang
pre-releas estim howev key chang comp estim
concept highlight follow
oliv garden ttm sale rais comp
estim although off-premis sale growth deceler
y/i follow increas past three year still expect
posit transact growth given core menu valu strong target promot
also anticip modest comp upsid next quarter expect
addit peer closur next quarter
longhorn ttm sale rais comp estim
along oper improv believ help longhorn
valu proposit believ longhorn see increment sale growth
cheddar ttm sale lower comp estim
yesterday call manag said would focu oper improv
notabl labor menu optim reduc size core menu
rather promot reason model comp
august novemb still anticip return posit comp
manag introduc increment sale layer off-premis
sale bring back promot
remain one top restaur pick believ share price upsid
remain share trade valuat revis ep estim
unchang price target base sum-of-part valuat
weigh dri mass-market casual dine concept higher-end fine dine
upscal casual concept franchise/licens incom use valuat year
price target also correspond company-wid forward price-to-earnings ratio vs
compani post-r lobster spin-off averag forward ev/ebitda
ratio vs compani post-r lobster spin-off averag ratio
click full note
identifi phase optim dose
contravir announc select optim formul
tenofovir exalidex txl txl formul optim compani
set conduct dose-rang studi hepat viru hbv patient
studi yield data pharmacokinet pk profil new txl
formul identifi dose util phase registr
new formula may improv txl deliveri liver work better
combin hbv treatment contravir precis
deliveri liver maintain efficaci reduc drug burden caus
less toxic side effect import consid hbv
drug combin regimen develop achiev function cure
conclus txl formul optim cyclophilin
inhibitor move clinic hbv contravir hbv program continu
progress goal combin txl view
contravir could attract partner pharma compani look
develop hbv regimen txl backbon phase dose find next
optim dose set stage phase studi
hing hbv take combin regimen
goal contravir ultim posit hbv candid txl tenofovir prodrug
essenti similar gilead taf believ superior viread
backbon compon hbv regimen could next piec bolt
view addit txl could attract pharma partner backbon
hbv regimen vs partnering/licens gilead buy
studi conduct clinic site three part follow first
part assess safeti toler pk profil administr
singl dose healthi volunt second part studi singl dose
drug-drug interact pilot studi stabl hbv patient co-treat
viread third part studi assess safeti toler pk preliminari
signal antivir efficaci identif clinically-relev biomark
viread stabl hbv patient addit hbv may also potenti
liver indic includ liver cancer fibrosi demonstr
reduct liver fibrosi nash space activ vs control
addit posit preclin data liver cancer hepb
click full note
zytiga prostat cancer
trovagen announc start enrol trial evalu
zytiga metastat castration-resist prostat cancer mcrpc
second clinic program underway studi detail
studi acut myeloid leukemia aml combin
decitibin recent complet dose first cohort see june
report move second cohort
focu drive clinic program trovagen valuat low-end
rang attribut fundament surround
develop rather financ overhang resolv
recent estim trovagen cash balanc sheet
runway two trial enrol expect data
believ trovagen posit execut clinic strategi
reach next set catalyst posit unlock valu
prostat cancer phase trial enrol patient mcrpc
show sign diseas progress demonstr two rise valu
separ least one week abiraterone/prednison therapi follow-
patient occur approxim everi six week diseas progress
patient stabl diseas better end treatment assess
studi evalu proport patient achiev diseas control week
studi treatment expect data studi conduct three
distinguish medic center dana-farber/massachusett gener hospit beth
israel deaco medic center phase trial also includ follow
effect combin abirateron prednison time
progress subject mcrpc
effect combin abirateron prednison time
radiograph progress base prostat cancer work group
guidelin
effect combin abirateron prednison
radiograph respons per respons evalu criteria solid tumor recist
criteria subject mcrpc measur diseas
preclin data demonstr synergi oral highli select kinas
inhibitor combin zytiga zytiga potent irrevers inhibitor
critic enzym androgen biosynthesi indic treatment
mcrpc co-administ prednison landscap
treatment mcrpc expand drug zytiga xtandi
extend surviv month pend posit data combin may abl
prolong surviv extend period patient
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
